Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
On Friday, H.C. Wainwright analyst Andres Maldonado updated the price target for Werewolf Therapeutics Inc. (NASDAQ:HOWL) to $10.00, down from the previous target of $15.00, but retained a Buy rating on the stock. Currently trading at $0.87 with a market cap of $39 million, the stock maintains a strong Buy consensus among analysts, with targets ranging from $4 to $15. According to InvestingPro data, the stock has fallen over 84% in the past year, suggesting significant upside potential if analyst targets materialize. The adjustment reflects a more risk-averse capital markets environment.
Werewolf Therapeutics’ ongoing Phase 1/1b trial of WTX-124 is progressing as planned, with all monotherapy and combination expansion arms actively enrolling participants. The company maintains a solid financial foundation for its clinical programs, with InvestingPro analysis showing a healthy current ratio of 8.09 and more cash than debt on its balance sheet. WTX-124 is an IL-2 INDUKINE molecule being tested alone or in combination with pembrolizumab in patients with various types of cancer, including melanoma, renal cell carcinoma (RCC), cutaneous squamous cell carcinoma (CSCC), and non-small cell lung cancer (NSCLC).
The data presented thus far remains consistent, with the monotherapy arm showing objective responses at doses of 12mg or higher and a durable complete response (CR) in CSCC that has continued for over 18 months without the drug. The combination arms have also demonstrated confirmed responses in melanoma patients who were refractory to immune checkpoint inhibitors (ICI), with durability exceeding eight months. Both treatment arms are using an 18mg dose every two weeks, which has been well-tolerated, with no Grade 2 or higher cytokine release syndrome (CRS), no vascular leak issues, and no new safety concerns in combination settings.
Looking forward, an interim data update is expected in the fourth quarter of 2025, which will provide insights into response durability, objective response rates (ORR) in expansion cohorts, and depth of response. These factors are anticipated to contribute to the de-risking of regulatory discussions, also scheduled for late 2025. The analyst expressed confidence in WTX-124’s potential to become a leading IL-2 therapy in the current medical landscape.
Additionally, while the focus remains on the IL-2 and IL-12 readouts, H.C. Wainwright noted that Werewolf Therapeutics’ INDUCER platform could gain strategic importance if early preclinical tolerability data—such as silenced peripheral activity and zero cytokine leakage—are confirmed during the development candidate selection process. While the company’s EBITDA stands at -$72.65 million, InvestingPro analysis indicates an overall Financial Health score of "FAIR," suggesting adequate resources to advance its pipeline. The Buy rating was reiterated despite the reduced price target, reflecting the broader market sentiment. Subscribers to InvestingPro can access the comprehensive Pro Research Report for deeper insights into Werewolf Therapeutics’ financial health and growth prospects.
In other recent news, Werewolf Therapeutics has announced new findings for its IL-10 INDUKINE molecule, WTX-921, which shows promise in reducing tissue damage and inflammatory cytokine production in a mouse model of colitis. This advancement supports its potential as a targeted therapy for inflammatory bowel disease. Additionally, analysts at JMP have reiterated their Market Outperform rating for Werewolf Therapeutics, maintaining a price target of $4.00. The company is progressing in its clinical programs by selecting an 18 mg dose of WTX-124 for trials in melanoma and other cancers, with an interim data update expected in the fourth quarter of 2025.
Moreover, Werewolf Therapeutics plans to engage with the U.S. Food and Drug Administration later in 2025 to discuss potential accelerated approval pathways for WTX-124. In corporate governance, the company has appointed Dr. Anil Singhal to its board of directors following the resignation of Dr. Derek DiRocco. Dr. Singhal brings over three decades of experience in the biopharmaceutical industry and will serve on the Audit Committee. His compensation includes an annual fee and stock options, reflecting his commitment to the company’s future. These developments highlight Werewolf Therapeutics’ ongoing efforts in advancing its therapeutic pipeline and strengthening its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.